Synergy Pharmaceuticals: An Interesting Investment Ahead Of Multiple Catalysts
- Synergy is substantially undervalued over the long term.
- Plecanatide has the potential to generate significant revenue for Synergy.
- Continued Plecanatide development will provide many catalysts for shareholders.
- SP-333 will also help to provide the potential for growth over the long term.